Stock listing

Frankfurt:4KB Krystal Biotech, Inc. Aktie

German listing (Frankfurt) of Krystal Biotech, Inc. · home listing NASDAQ:KRYS

Follow Krystal Biotech, Inc. into a list and get an email when it puts out news.

Share price · FWB:4KB

€287.80 EUR +1.70 (+0.6%)

Close on Oct 30, 2026

Day range
€287.80 – €287.80 EUROct 30, 2026
Market cap
€8.52B EURAt the close on Oct 30, 2026 · price × 29.60M shares outstanding
Krystal Biotech, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:KRYS · Home$332.29 USD+7.74 (+2.4%)330,022$325.83$332.63$319.95$324.55Close on Oct 30, 2026
Frankfurt:4KB€287.80 EUR+1.70 (+0.6%)—€287.80€287.80€287.80€286.10Close on Oct 30, 2026
Ticker
Frankfurt:4KB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Upcoming

  • Krystal Biotech (NASDAQ:KRYS) Q3 2026 Earnings Call

    Mon, Nov 02, 2026 · 8:30 AM ET

    Register

Replays

  • Krystal Biotech (NASDAQ:KRYS) Q2 2026 Earnings Call

    Mon, Aug 03, 2026 · 8:30 AM ET

    Watch Transcript

  • Krystal Biotech (NASDAQ:KRYS) Q1 2026 Earnings Call

    Mon, May 04, 2026 · 8:30 AM ET

    Watch Transcript

  • Krystal Biotech (NASDAQ:KRYS) Q4 2025 Earnings Call

    Tue, Feb 17, 2026 · 8:30 AM ET

    Watch Transcript

Latest news

Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026

Oct 22, 2026

Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome

Oct 15, 2026

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

Sep 3, 2026

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

Aug 3, 2026

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

Jul 23, 2026

Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600

Jul 20, 2026

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

May 18, 2026

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

May 7, 2026

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

May 4, 2026

Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

Apr 21, 2026

All Krystal Biotech, Inc. news

Decks

Krystal Biotech, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
21 in the last 12 months · 181 in all · newest Oct 22, 2026 · oldest 2019
Calls
12 calls with a replay · 12 with a transcript · latest Aug 3, 2026
Decks
33 decks · latest Aug 3, 2026

Where Krystal Biotech, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:KRYS · Home listingNASDAQUnited StatesUSD
gettex:4KBgettexGermanyEUR
Tradegate:4KBTradegateGermanyEUR
LS Exchange:A2JH2FLS ExchangeGermanyEUR
Lang & Schwarz:A2JH2FLang & SchwarzGermanyEUR
Milan:1KRYSMilanItalyEUR
BOATS:KRYSBOATSUnited StatesUSD
BX Swiss:KRYSBX SwissSwitzerlandCHF
B3:K1YS34B3BrazilBRL
Munich:4KBMunichGermanyEUR
Stuttgart:4KBStuttgartGermanyEUR
Dusseldorf:4KBDusseldorfGermanyEUR
Frankfurt:4KB · This pageFrankfurtGermanyEUR
Hamburg:4KBHamburgGermanyEUR
Hanover:4KBHanoverGermanyEUR
Xetra:4KBXetraGermanyEUR

Log in to ask 6ix AI your own questions about Krystal Biotech, Inc.